MetaCap

Agenus Inc. (AGEN)

NASDAQ: AGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

5.97-0.17 (-2.77%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AGEN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$270.12M
52-week range
2.71 – 10.31
Day range
5.90 – 6.26
Volume / Avg
711.70K / 905.17K
Beta
—

52-week range

$2.71$10.31

AGEN stock today

Shares of Agenus (AGEN) finished lower on Nov 20 at $5.97, a drop of 2.77% or $0.17 per share, versus the S&P 500's 3.70% decline. Shares are 42.1% below their 52-week high of $10.31, set on Sep 30, 2026 and 120.3% above the 52-week low of $2.71, in the middle of the past year's range. AGEN is up 90.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 41.5%.

Agenus trades at 26.0x its trailing twelve-month earnings per share of $0.23.

Summary generated from market data by MetaCap's automated system. Methodology

About Agenus

Company profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Garo H. Armen Ph.D.
Headquarters
Lexington, MA
Employees
81
IPO year
2000

Financial highlights

Full financials

In fiscal 2025, Agenus generated $114.2 million in revenue, up 10.4% from fiscal 2024. Agenus reported a net loss of $3.1 million, compared with a loss of $232.3 million a year earlier. Gross margin was 99.1% (down from 99.5%) and operating margin -17.7%.

Agenus annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$114.20M$103.46M$156.31M$98.02M$295.67M
Growth+10.37%-33.81%+59.47%-66.85%+235.34%
Net income$-3.08M$-232.27M$-257.44M$-230.66M$-28.72M
EPS (diluted)$0.00$-10.59$-13.75$-15.64$-0.11

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$27.00+352.26%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $16.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$0.02 vs $0.02

AGEN news

All AGEN news

Agenus peers

Health Care sector
AGEN peer companies
CompanyPrice% ChgMarket capCompare
KYTXKyverna Therapeutics Inc.4.26-2.52%$269.33Mvs AGEN
AGMBAgomAb Therapeutics NV ADR5.45-3.02%$268.40Mvs AGEN
OCGNOcugen Inc.0.7679+4.79%$260.55Mvs AGEN
DTILPrecision BioSciences Inc.7.40+7.09%$282.46Mvs AGEN
EIKNEikon Therapeutics Inc.4.74-0.42%$256.84Mvs AGEN
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs AGEN
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs AGEN
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs AGEN

Indexes, lists and sector

Agenus stock FAQ

What is Agenus's stock price today?

AGEN last traded at $5.97 as of Nov 20, 4:00 PM EST, down 2.77% on the day. Prices are delayed at least 15 minutes.

Does Agenus pay a dividend?

No. Agenus does not currently pay a regular cash dividend.

What is AGEN's P/E ratio?

AGEN trades at a trailing P/E ratio of 25.96.

Who is Agenus's CEO?

Dr. Garo H. Armen Ph.D. is the chief executive officer of Agenus Inc., which has about 81 employees.

Has AGEN ever split its stock?

Yes. The most recent AGEN stock split was a 1-for-20 split on Apr 12, 2024, one of 3 splits on record.

What is the AGEN 52-week high?

The 52-week high for AGEN is $10.31 and the 52-week low is $2.71. The stock is currently 42.1% below its high.

Compare AGEN